metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology NAFLD-MASLD-MAFLD continuum: A swinging pendulum?
Información de la revista
Vol. 29. Núm. 5.
(septiembre - octubre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. 5.
(septiembre - octubre 2024)
Letters to the editor
Acceso a texto completo
NAFLD-MASLD-MAFLD continuum: A swinging pendulum?
Visitas
372
Mariana M. Ramírez-Mejía
Plan of Combined Studies in Medicine (PECEM-MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico
Xingshun Qi
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Liaoning Province, China
Ludovico Abenavoli
Department of Health Sciences, University Magna Graecia of Catanzaro, Italy
Beatriz Barranco-Fragoso
Department of Gastroenterology, National Medical Center "20 de Noviembre", ISSSTE, Mexico City, Mexico
Sandra M. Barbalho
Department of Biochemistry and Pharmacology, School of Medicine, University of Marília, Marília, São Paulo, Brazil
Nahum Méndez-Sánchez
Autor para correspondencia
Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
To the editor:

We read with interest the study by Pan and colleagues showing that criteria for metabolic dysfunction associated fatty liver disease (MAFLD) are superior to metabolic dysfunction associated steatotic liver disease (MASLD) in identifying individuals at risk of chronic kidney disease [1]. This study is consistent with what we and others have recently demonstrated that MAFLD outperforms MASLD in identifying metabolic dysfunction, fibrosis, cardiovascular disease and mortality [2-5]

The concept of MASLD is derived from MAFLD. It is not a secret that the proponents of MASLD have been vocal in their resistance accepting the MAFLD definition and opposing the mainstream in the field, opting to accept anything rather than MAFLD including even retaining the clinical status quo despite its limitations. This leads to an intriguing question: is the NAFLD-MASLD-MAFLD continuum merely the pendulum clock swinging back and forth? NAFLD and MAFLD are like 12 and 6 on a clock, representing 180-degree different concepts. MASLD, on the other hand, represents a movement of the clock and falls somewhere between 3 and 4 on the clock, closer to MAFLD. In support of this hypothesis, the discussion has shifted currently from do we need the change or not to what this change should be. Thus, perhaps MASLD represents another phase of transient resistance to MAFLD, while the pendulum continues to move. This could at least partially explain the accumulating recent data suggest that the MAFLD definition performs better than the MASLD definition [2,4,5]. This outcome is curious, as new definitions should provide substantial conceptual advances over previous ones; alternatively what is the point of the change. As the key purpose of the MASLD proposal was likely just to resist the widespread of the endorsement of MAFLD rather than devoting the effort and getting benefit of the opportunity of coming second to provide an actual conceptual advance capitalising on the MAFLD definition.

Interestingly, it took more than a decade for Helicobacter pylori to be universally accepted, which became known as the "gastric ulcer war" [6]. Only time will tell if the same will happen for the NAFLD-MASLD-MAFLD continuum, and if so, how long will it take.

Funding

None

References
[1]
Z. Pan, M. Derbala, K. AINaamani, H. Ghazinian, J.G. Fan, M. Eslam.
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
Ann Hepatol, (2024),
[2]
M.M. Ramírez-Mejía, C. Jiménez-Gutiérrez, M. Eslam, J. George, N. Méndez-Sánchez.
Breaking new ground: MASLD vs. MAFLD—Which holds the key for risk stratification?.
Hepatol Int, 18 (2024), pp. 168-178
[3]
Z. Pan, G. Shiha, G. Esmat, N. Méndez-Sánchez, M. Eslam.
MAFLD predicts cardiovascular disease risk better than MASLD.
Liver International, (2024),
[4]
Z. Pan, M. Eslam, A. Choudhury, B. Sahoo, C.R. Lesmana, F.M. Sanai.
The MASLD criteria overlook a number of adolescent patients with severe steatosis.
J. Hepatol., (2024),
[5]
X.-D. Zhou, A. Lonardo, C.Q. Pan, M.D. Shapiro, M.-H. Zheng, K.I. Zheng, et al.
Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or Both.
J. Hepatol., (2024),
[6]
S Guide, P Embargo, A Home, A Mobile.
The Great Ulcer, War: how It All Happened, (2014),
Copyright © 2024. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2024.101535
No mostrar más